HCPLive’s Post

Transcript

Given the 80 landscape has changed so dramatically over the last several years, I think this is a nice time for us to be able to talk about not only the various treatments that we have, but also how do we optimize treatment for patients by taking those treatments and appropriately giving them to the patients that are in need and defining what is adequate control. What is that bar for efficacy that we should be reaching for? Because really for the longest time for our patients with atopic dermatitis, we didn't have much. And now that we have so many different options, even though it's exciting, it can also be a little bit overwhelming. So the revolutionizing atopic dermatitis meeting AKA RAD really does just that. And this year it's going to be in Nashville, a great place to attend in person. And it's going to focus not only on optimizing that management of our patients with our currently FDA approved therapies, but also we're going to dive into some new therapies on the horizon, exciting options for our. Patients to help them achieve even better adequate Disease Control. But also we're going to look at some of the unseen burdens of disease. And it's a 2 day conference. It's going to go through the spectrum of atopic dermatitis related topics. We're going to discuss the psychosocial burden of AD and I have the privilege of speaking on that aspect of the disease. But also advancements in Jack inhibitors, complex cases involving atopic dermatitis and hair loss, some of the new therapeutic approvals. How do you manage itch? Which we know is one of the most significant issues that are atopic struggle with. And then we're also going to talk about some special considerations when you're treating kids with ADHD because there's more that goes into that dynamic besides just me and the patient. There's a caregiver and a parent involved as well. And how do you really navigate that with all the emerging treatments that we have on the horizon? And also one thing I've always loved about RAD is the cutting edge research that is showcased at this particular meeting because I know. For myself, I'm going to be submitting an abstract for this meeting in particular, but it's really where I go where I want to see some of the latest data that may not be ready for manuscript production yet, but you want to get it into the hands of clinicians so they can apply that data to their real world clinical practice.